In the latest trading session,, 2.07 million Enveric Biosciences Inc (NASDAQ:ENVB) shares changed hands as the company’s beta touched 0.55. With the company’s most recent per share price at $1.27 changed hands at -$0.03 or -2.30% at last look, the market valuation stands at $3.14M. ENVB’s current price is a discount, trading about -944.88% off its 52-week high of $13.27. The share price had its 52-week low at $1.01, which suggests the last value was 20.47% up since then.

Enveric Biosciences Inc (NASDAQ:ENVB) trade information

Instantly ENVB was in red as seen in intraday trades today. With action -6.27%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -76.37%, with the 5-day performance at -6.27% in the red. However, in the 30-day time frame, Enveric Biosciences Inc (NASDAQ:ENVB) is 8.56% up.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.47%. The 2025 estimates are for Enveric Biosciences Inc earnings to increase by 38.66%.

ENVB Dividends

Enveric Biosciences Inc is expected to release its next quarterly earnings report in June.

GEODE CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 1.1161% or 44659.0 shares worth $27688.0 as of 2024-06-30.

Among Mutual Funds, the top two as of Apr 30, 2025 were AdvisorShares Trust-AdvisorShares Psychedelics ETF and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . With 90.32 shares estimated at $0.12 million under it, the former controlled 3.65% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.51% of the shares, roughly 12.59 shares worth around $16384.0.